Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2016 Q2- Text added to 2016 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
acquire, acquired, addressing, adequate, advisory, aggressive, anticancer, Bethesda, biological, BL, Boston, breast, cancer, candidate, Chaturvedi, chemical, chemotherapeutic, chemotherapy, Delaware, descent, distinct, DNA, eligible, emerging, endometrial, excellent, FIH, forma, genomic, gynecological, illustrative, IND, Institute, Investigational, lead, MD, member, Merger, metastatic, molecular, multiple, NCI, November, oncology, opportunistically, PBD, Pharma, poor, portfolio, Pravin, preclinical, predominantly, prioritized, pro, pursuit, pvt, pyrrolobenzodiazepine, recent, remaining, render, rendering, repair, replication, repurposing, resistant, response, Scientific, seeking, show, Sindu, subsidiary, subtype, support, therapy, TNBC, unmet, urological, vesting, wholly, younger
Valuein 2016 Q2 filing- Value in 2016 Q3 filing
Original filings
Filing view